These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22972034)

  • 1. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
    Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
    Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
    Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
    Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
    Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
    Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
    Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
    Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
    Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
    Saha MN; Abdi J; Yang Y; Chang H
    Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
    Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
    Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
    Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
    Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
    Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
    PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
    Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
    Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
    Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
    Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
    Marango J; Shimoyama M; Nishio H; Meyer JA; Min DJ; Sirulnik A; Martinez-Martinez Y; Chesi M; Bergsagel PL; Zhou MM; Waxman S; Leibovitch BA; Walsh MJ; Licht JD
    Blood; 2008 Mar; 111(6):3145-54. PubMed ID: 18156491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
    Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
    Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
    [No Abstract]   [Full Text] [Related]  

  • 16. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
    Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
    Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
    Kuo CH; Chen KF; Chou SH; Huang YF; Wu CY; Cheng DE; Chen YW; Yang CJ; Hung JY; Huang MS
    Carcinogenesis; 2013 Nov; 34(11):2600-9. PubMed ID: 23955539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
    Lin TC; Lin PL; Cheng YW; Wu TC; Chou MC; Chen CY; Lee H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1532-9. PubMed ID: 25990966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.